In a new study, PricewaterhouseCoopers presents a country-by-country analysis of the Asian biopharmaceutical scene. The purpose of the review is to determine which countries are the best for outsourcing or locating new biopharma facilities. In the report, titled “The Changing Dynamics of Pharma Outsourcing in Asia," each country’s desirability is determined by evaluating three major areas of consideration: Cost, Safety and Market. Each of these categories is broken down into smaller areas, and then the individual considerations are weighted by importance.  The winners? China, India and Singapore.  More details...